A Phase I Trial of Olaparib in Addition to Cisplatin-based Concurrent Chemoradiotherapy for Patients With High Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck (NHSCC)
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 4
- 主要终点
- Occurrence of Dose Limiting Toxicity
研究概览
简要总结
The phase I trial aims to determine the recommended phase II dose (RP2D) and schedule of olaparib in combination with standard cisplatin-based chemoradiotherapy, in patients with high-risk locally advanced squamous cell carcinoma of the head and neck (HNSCC), by assessing the safety and tolerability of the treatment combination.
详细描述
ORCA-2 is a phase I trial in patients with locally advanced, with or without metastatic nodal disease.
Patients will receive olaparib (a PARP inhibitor) in combination with standard cisplatin-based chemotherapy and intensity modulated radiotherapy (IMRT).
Olaparib, cisplatin and radiotherapy will be given in combination every week for a maximum of 7 weeks. Prior to starting combination treatment, olaparib will be started 7 days before the first week of combination treatment. Olaparib will be given twice daily on days 1-3 of each week of treatment (either alone during week 0 or in combination with chemotherapy and radiotherapy during weeks 1-7). Cisplatin will be started on day 1 of each week, and given once a week during radiotherapy treatment for a total of 7 weeks. Radiotherapy will be delivered on days 1-5 of each week using IMRT, for a total of 7 weeks.
The phase I trial aims to determine the recommended phase II dose of olaparib (50mg, 100mg, 150mg or 200mg bd) - the dose of olaparib patients receive will depend on the dose under investigation at the time of patient registration.
Dose escalation will be guided by the two-dimensional dose escalation design called Product of Independent Beta Probabilities escalation (PIPE). It will recommend the choice of dose/duration combination cohort of olaparib for subsequent patients by estimating the contour that divides dose/duration combination cohorts to be those above the target toxicity rate (equal to 33%) and those below. The recommended phase II cohort(s) are those that have been experimented on during the trial and are also closest to (but not above) the estimated contour calculated using all trial data.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed high-risk locally advanced HNSCC, patients who would normally be offered cisplatin-based radical chemoradiotherapy
- •Estimated life expectancy of at least 16 weeks
- •WHO performance status 0 or 1
- •Aged ≥18 years
- •Adequate bone marrow function: absolute neutrophils grade 0 or 1, platelets grade 0 or 1, haemoglobin grade 0 or 1
- •Adequate renal function: Creatinine grade 0 or 1, Calculated GFR ≥60 mL/min (if calculated value is <60 mL/min then an isotope GFR assessment should be performed or an estimation from 24h urine collection)
- •Adequate liver function: Serum bilirubin grade 0 or 1, AST or ALT grade 0 or 1
- •Patients must be able to swallow olaparib tablets
- •Willing to use contraception for the duration of the trial treatment and for six months after completion of treatment
- •Able to give informed consent
- •Patients willing and able to comply with the protocol for the duration of the study
排除标准
- •Head & neck cancers of the following types: Nasopharyngeal and paranasal sinus tumours, Oral squamous cell carcinomas (tumours of the oral cavity), Low risk Human Papilloma Virus positive oropharyngeal tumours (tonsillar and tongue base tumours)
- •Confirmed distant metastatic disease
- •Previous chemotherapy or radiotherapy for the treatment of HNSCC tumour
- •Previous therapy with a PARP inhibitor
- •Chemotherapy, immunotherapy or radiotherapy within 28 days prior to registration
- •Prior history of malignancy, except for basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, breast or prostate. Patient must have been free of malignancy for a period of 3 years prior to first dose of trial drug
- •Women who are pregnant or lactating
- •Pre-existing gastrointestinal disorders that may interfere with the delivery or absorption of olaparib
- •Grade 3 or 4 peripheral neuropathy - If considered significant by the treating clinician a lower grade neuropathy may be considered as exclusion criterion
- •Significant hearing difficulties or tinnitus (deaf patients can be included) - Whilst not excluded, patients with mildly impaired hearing or tinnitus must be made aware of potential ototoxicity and may choose not to be included. If included, it is recommended that audiograms be carried out at baseline.
- •Any serious and/or unstable pre-existing medical, psychiatric or other condition that, in the treating clinician's judgment, could interfere with patient safety or obtaining informed consent
- •Known hepatitis B or C infection (testing for Hepatitis and HIV for the trial is not mandatory)
- •Immunocompromised patients (e.g. known HIV positive status)
- •Active uncontrolled infection
- •The current use of drugs which are known to inhibit or induce CYP3A4
- •Resting ECG with QTc > 470msec on 2 or more time points within a 24 hour period or family history of long QT syndrome.
- •Patients with myelodysplastic syndrome/acute myeloid leukaemia.
- •Patients with a known hypersensitivity to olaparib or any of the excipients of the product.
研究组 & 干预措施
Olaparib + Cisplatin + IMRT
Olaparib: 50, 100, 150 or 200 mg twice a day for between 3-5 sequential days, depending on cohort allocation, in combination with Cisplatin: 35 mg/m^2 on day 1, and IMRT: 2 Gy radiotherapy given on days 1-5
Treatment will start on day 1 of every week. Patients will receive up to 7 weeks of combination chemotherapy and radiotherapy treatment.
干预措施: Cisplatin (Drug)
Olaparib + Cisplatin + IMRT
Olaparib: 50, 100, 150 or 200 mg twice a day for between 3-5 sequential days, depending on cohort allocation, in combination with Cisplatin: 35 mg/m^2 on day 1, and IMRT: 2 Gy radiotherapy given on days 1-5
Treatment will start on day 1 of every week. Patients will receive up to 7 weeks of combination chemotherapy and radiotherapy treatment.
干预措施: IMRT (Radiation)
Olaparib + Cisplatin + IMRT
Olaparib: 50, 100, 150 or 200 mg twice a day for between 3-5 sequential days, depending on cohort allocation, in combination with Cisplatin: 35 mg/m^2 on day 1, and IMRT: 2 Gy radiotherapy given on days 1-5
Treatment will start on day 1 of every week. Patients will receive up to 7 weeks of combination chemotherapy and radiotherapy treatment.
干预措施: Olaparib (Drug)
结局指标
主要结局
Occurrence of Dose Limiting Toxicity
时间窗: From start of week 1 to 6 weeks after end of combination treatment (combination treatment = 7 weeks)
Detailed adverse event monitoring will be conducted according to CTCAE v4.03. Dose Limiting Toxicity (DLT) is defined as any adverse event or laboratory abnormality detailed in the trial protocol, that is considered to be trial treatment related and commencing anytime during the DLT evaluation period (from start of week 1 of olaparib + CRT until 6 weeks after end of olaparib + CRT).
次要结局
- Time to Loco-Regional Progression(From date of registration to date of documented disease progression, assessed up to 2 years from date of registration)
- Occurrence and Severity of Adverse Events(From date of registration until 12 weeks after completion of trial treatment)
- Best Overall Response(Determined from imaging/scans performed pre-registration, during treatment and follow-up until disease progression or up to 2 years from date of registration)
- Time to Progression(From date of registration to date of documented objective disease progression)
- Progression Free Survival(From date of registration to date of documented disease progression or death from any cause, whichever comes first. Assessed up to 2 years from date of registration.)
- Overall Survival(From date of registration until date of death or date of last follow-up assessment (up to 2 years from date of registration))